News - Research, Aubagio

Filter

Current filters:

ResearchAubagio

Popular Filters

Aubagio significantly reduced risk of new clinical relapse or MRI lesion in MS study

03-10-2013

French drug major Sanofi and its subsidiary Genzyme announced positive new data from the TOPIC study…

AubagioGenzymeNeurologicalPharmaceuticalResearchSanofi

Sanofi's Aubagio delayed onset of clinically definite MS in TOPIC study

25-04-2013

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme announced today positive top-line…

AubagioBiotechnologyGenzymeNeurologicalPharmaceuticalResearchSanofi

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

14-10-2012

New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Sanofi's Aubagio reduces MS relapse; firm aims to build diabetes portfolio

01-06-2012

Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) today reported top-line results from…

AubagioBiotechnologyDiabetesGenzymeMergers & AcquisitionsNeurologicalPharmaceuticalResearchSanofiteriflunomide

FDA strengthens warnings on Sanofi’s Multaq; Aubagio disappoints

20-12-2011

The US Food and Drug Administration (FDA) has completed a safety review of French drug major Sanofi’s…

AubagioCardio-vascularMultaqNeurologicalPharmaceuticalRegulationResearchSanofi

Sanofi pays $3 million milestone to ImmunoGen on start of SAR3419 Ph II testing; FDA accepts Aubagio filing

21-10-2011

US biotech firm ImmunoGen (Nasdaq: IMGN) says that SAR3419 has started Phase II testing, which triggers…

AubagioBiotechnologyFinancialGenzymeImmunoGenNeurologicalOncologyPharmaceuticalRegulationResearchSanofi

Sanofi oral MS drug Aubagio shows strong efficacy in Ph III trial; plans massive Indian vaccine plant

07-10-2011

French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme says that the results of a pivotal…

Asia-PacificAubagioFinancialGenzymeNeurologicalPharmaceuticalResearchSanofiShanthaVaccines

Back to top